UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010295
Receipt number R000010947
Scientific Title Phase 1/2 clinical trial of image-guided hypofractionated intensity-modulated radiotherapy/volumetric modulated arc therapy for localized low- or intermediate-risk prostate cancer
Date of disclosure of the study information 2013/03/22
Last modified on 2023/04/11 17:55:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase 1/2 clinical trial of image-guided hypofractionated intensity-modulated radiotherapy/volumetric modulated arc therapy for localized low- or intermediate-risk prostate cancer

Acronym

Image-guided IMRT/VMAT for localized prostate cancer

Scientific Title

Phase 1/2 clinical trial of image-guided hypofractionated intensity-modulated radiotherapy/volumetric modulated arc therapy for localized low- or intermediate-risk prostate cancer

Scientific Title:Acronym

Image-guided IMRT/VMAT for localized prostate cancer

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate efficacy of image-guided hypofractionated intensity-modulated radiotherapy/volumetric modulated arc therapy of 70.2Gy in 27 fractions using fiducial gold markers for localized low- or intermediate-risk prostate cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase I,II


Assessment

Primary outcomes

5-y biochemical relapse free survival

Key secondary outcomes

5-y distant metastasis free survival
5-y cause-specific survival
5-y overall survival
Toxicity (acute and late)


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment Maneuver

Interventions/Control_1

Patients are treated with image-guided hypo fractionated IMRT/VMAT (67.6Gy/26fx.) using fiducial gold markers in the prostate.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

1) Prostate adenocarcinoma is proven.
2) Patient should receive MRI examination before treatment.
3) cT1-T2N0M0, Gleason score<or=7, pretreatment PSA <20ng/ml
4) ECOG PS 0-1
5) Patients must sign informed consent form prior to registration

Key exclusion criteria

1) Prior pelvic radiotherapy
2) Small cell carcinoma
3) cT3-4, exist of metastasis
4) Prior prostatectomy
5) Concurrent invasive cancers or collagen disease
6) PSA failure following hormonal therapy
7) If the attending physician judges the case inappropriate.
8) Gold allergy
9) Severe diabetes mellitus
10) Usage of anticoagulants/antiaggregant
11) Biochemical failure after hormonal therapy
12) Difficult to comply with dose constraints
13) IPSS>or=20

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Ken
Middle name
Last name Takeda

Organization

Health Sciences, Tohoku University Graduate School of Medicine

Division name

Department of Therapeutic Radiology

Zip code

980-8575

Address

2-1, Seiryomachi, Aobaku, Senddaishi

TEL

022-717-7909

Email

ken.takeda.a3@tohoku.ac.jp


Public contact

Name of contact person

1st name Ken
Middle name
Last name Takeda

Organization

Tohoku University Hospital

Division name

Department of Radiation Oncology

Zip code

980-8574

Address

1-1, Seiryomachi, Aobaku, Sendaishi

TEL

022-717-7312

Homepage URL


Email

ken.takeda.a3@tohoku.ac.jp


Sponsor or person

Institute

Tohoku University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tohoku University Hospital Clinical Research Ethics Committee

Address

1-1, Seiryomachi, Aobaku, Sendaishi

Tel

022-717-7145

Email

med-kenkyo@bureau.tohoku.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東北大学病院


Other administrative information

Date of disclosure of the study information

2013 Year 03 Month 22 Day


Related information

URL releasing protocol

none

Publication of results

Unpublished


Result

URL related to results and publications

none

Number of participants that the trial has enrolled

12

Results

A total of 12 patients were enrolled from March 2013 to April 2017 after institutional ethics committee approval. The study was terminated in November 2017 because the target number was not reached. No serious adverse events of Grade 3 or higher were observed in either the gastrointestinal tract or the urinary tract during the period. No biochemical recurrence was observed within the period.

Results date posted

2023 Year 04 Month 11 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Prostate cancer cases in men in their 50s to 70s.

Participant flow

Participated by referral from the Department of Urology at Tohoku University Hospital or urological department at another Hospital.

Adverse events

No serious adverse events of Grade 3 or higher were observed in either the GI or GU.

Outcome measures

PSA failure, late side effect

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 11 Month 01 Day

Date of IRB

2012 Year 10 Month 23 Day

Anticipated trial start date

2012 Year 10 Month 23 Day

Last follow-up date

2017 Year 11 Month 30 Day

Date of closure to data entry

2017 Year 11 Month 30 Day

Date trial data considered complete

2017 Year 11 Month 30 Day

Date analysis concluded

2018 Year 01 Month 30 Day


Other

Other related information



Management information

Registered date

2013 Year 03 Month 22 Day

Last modified on

2023 Year 04 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010947


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name